Novo Nordisk (NVO) Chairman Helge Lund and six independent directors are stepping down after a dispute with the Novo Nordisk Foundation, the drugmaker’s majority shareholder, The Financial Times’ Hannah Kuchler reports. “Following dialogue with the Novo Nordisk Foundation regarding the future composition of the board of directors, it has not been possible to reach a common understanding,” Lund said. The foundation is putting forward five candidates for the board, including Lars Rebien Sorensen as chair, and will nominate another two next year, according to the report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk to Convene Extraordinary General Meeting for Board Election
- Novo Nordisk Announces Extraordinary General Meeting for Board Elections
- Novo Nordisk announces FDA approval of Rybelsus
- Midday Fly By: Apple new F1 broadcast partner, CSX reports Q3 beat
- Casual Dining Stocks: Feeling Down in the Mouth as Festive Economy Freezes